Dr. Ramalingam on the Clinical Examination of Patritumab Deruxtecan in NSCLC

In Partnership With:

Partner | Cancer Centers | <b>Winship</b>

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the exploration of patritumab deruxtecan in non–small cell lung cancer.

Suresh S. Ramalingam, MD, FACP, FASCO, director, Lung Cancer Program, Winship Cancer Institute of Emory University, professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses the exploration of patritumab deruxtecan (U3-1402) in non–small cell lung cancer (NSCLC).

HER3 is activated as one of the acquired mechanisms of resistance in NSCLC, and the antibody-drug conjugate (ADC) patritumab deruxtecan targets that pathway, Ramalingam says. Preclinical studies have investigated patritumab deruxtecan as a treatment option for patients EGFR-mutated NSCLC who developed resistance to EGFR TKIs, Ramalingam continues.

In the phase 1 U31402-A-U102 trial (NCT03260491), 5.6mg/kg of single-agent patritumab deruxtecan elicited an overall response rate of 39% in 57 patients with EGFR-positive NSCLC who had prior exposure to a TKI and platinum-based chemotherapy, Ramalingam explains. The median progression-free survival was 8.2 months for this cohort of patients, Ramalingam adds. Additional ongoing trials are further investigating the use of patritumab deruxtecan in this patient population, Ramalingam concludes.

Funding from Daiichi Sanyko. Content Developed Independently by OncLive.